Dr Ben Bolton-Maggs, a consultant orthopaedic surgeon at Whiston Hospital, who is a fan of this system, said: ``I use autologous
transfusions if at all possible.
Some 30,000 autologous
transplants were performed in 1998, with 30 percent of them for breast cancer.
Nearly 20 percent of the respondents also reported that they had seen patients erroneously receive conventional blood before receiving a transfusion of their own blood, which can defeat the purpose of autologous
marrow transplants among breast cancer patients are "going gangbusters," he says, with hundreds performed per year despite a relative shortage of data regarding the technique's ultimate benefits.
Through clerical error, which is the primary cause of transfusion accidents" these patients could receive infected blood that had been intended for autologous
FCSC) is an autologous
cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications.
Analyzes and evaluates autologous
tissue repair products and product candidates and assesses the market potential for existing and probable future products
orthobiologic is traditionally used in surgical fields such as Spine and Sports Medicine.
We attempted to develop an autologous
platelet gel biologic dressing that would improve the re-epithelialization process following the creation of superficial laser skin burns.
The researchers assessed outcomes in 157 patients with relapsed or refractory Hodgkin's disease who underwent BMT (allogeneic - 53; autologous
- 104) between 1985 and 1998.
The inaugural DATTA Forum meeting convened representatives of more than 80 major payers, HMOs, and medical centers to discuss the issue of autologous
bone marrow transplantation for breast cancer.
In most cases, doctors give the compounds in conjunction with an autologous
bone marrow transplantation, removing a sample of the patient's marrow before chemotherapy, then reinfusing it with CSFs to quickly "reseed" the marrow and blood supply with new white blood cells.
donation program in a January 1985 MLD article.
OTCBB: FCSC), a biotechnology company focused on the development of autologous
(personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company's Chairman and CEO, will be presenting at the ROTH 23rd Annual OC Growth Stock Conference to be held on March 13-16 at the Ritz-Carlton in Laguna Niguel, California.
NYSE MKT:FCSC), an autologous
cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, and Intrexon Corporation(NYSE: XON), a leader in synthetic biology, announced today an expansion of their Exclusive Channel Collaboration (ECC) to develop a treatment for Ehlers-Danlos syndrome hypermobility type (EDS-HT), a rare genetic disorder resulting in weakened connective tissue.